期刊文献+

基因沉默孤儿核受体ERRα抑制前列腺癌细胞的体内转移 被引量:2

Knockdown ERRα Inhibits in Vivo Metastasis in Prostate Cancer Cells
原文传递
导出
摘要 目的:研究孤儿核受体ERRα对前列腺癌细胞E-cadherin(上皮细胞钙粘蛋白)的表达水平和体内转移能力的影响。方法:利用慢病毒介导的sh RNA构建稳定下调ERRα表达的DU145-sh ERRα和PC-3M-sh ERRα前列腺癌细胞模型,同时用ERRα特异性抑制剂XCT790抑制其活性,并利用Western Blotting(免疫印迹)检测上皮细胞标志物E-cadherin的表达水平。将PC-3M-sh ERRα细胞和PC-3M-scramble对照细胞用荧光素酶标记后原位注射小鼠前列腺,8周以后通过体内成像系统检测原位瘤的形成及其体内转移情况。结果:基因沉默ERRα表达水平和用其特异性抑制剂XCT790处理DU145后,E-cadherin的表达水平明显降低。在PC-3M-sh ERRα细胞中,E-cadherin的表达水平明显低于对照组,同时由其构建的6只原位前列腺癌小鼠模型中没有发生转移,而由对照组细胞构建的7只原位前列腺癌小鼠模型中有4只发生了转移。结论:在前列腺癌细胞中下调ERRα的表达水平抑制其E-cadherin的表达和体内转移能力。 Objective: To explore the roles of orphan nuclear receptor ERRα in E-cadherin expression regulation and in vivo metastasis in prostate cancer cells. Methods: DU145-shERRα and PC-3M-shERRα cell models were established by gene knockdown mediated by lentivirus. ERRct specifc antaguist XCT790 was used to inhibit its activity, the expression level of E-cadherin was identified by Western Blotting. PC-3M-shERRα and PC-3M-scramble cells were labeled by luciferase and injected in situ in mice prostate, metastases were measured through in vivo image system and indicated by the fluorescence intensity 8 weeks after injection. Results: The expression level of E-cadherin was significantly decreased in DU145 after knockdown ERRαor treatment with XCT790. The expression level of E-cadherin in PC-3M-shERRα was significantly suppressed as compared to that in control cells. Moreover, 4 of 7 in situ prostate cancer mice models dreived from PC-3M-scramble cells, while 0 of 6 from PC-3M-shERRα cells, develop metastases. Conclusions: Knockdown ERRα in prostate cancer cells attenuate E-cadherin expression and their in vivo metastasis.
出处 《现代生物医学进展》 CAS 2015年第10期1855-1857,1865,共4页 Progress in Modern Biomedicine
基金 广东省深圳市南山科技局项目(2012005)
关键词 ERRα E-CADHERIN 前列腺癌 体内转移 ERRα E-cadherin Prostate cancer In vivo metastasis
  • 相关文献

参考文献20

  • 1Shao Q, Ouyang J, Fan Y, et al. Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration [J]. Cancer Lctt, 2012, 315(2): 170-177.
  • 2Tanimoto T, Hori A, Kami M. SipuleuccI-T immunotherapy for prostate cancer [J]. N Engl J Med, 2010, 363(20) 1966; author reply 1967-1968.
  • 3Rehman Y, Rosenberg J E. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer[J]. Drug Des Devel Ther, 2012, 6:13-18.
  • 4Crawford E D, Flaig T W. Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches [J]. Ontology (Williston Park), 2012, 26(1): 70-77.
  • 5Francis G A, Fayard E, Picard F, et al. Nuclear receptors and the control of metabolism[J]. Annu Rev Physiol, 2003, 65:261-311.
  • 6Giguere V, Yang N, Segui P, et al. Identification of a new class of steroid hormone receptors[J]. Nature, 1988, 331(6151): 91-94.
  • 7Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors[J]. Endocr Rev, 2008, 29(6): 677-696.
  • 8Cai Q, Lin T, Kamarajugadda S, et al. Regulation of glycolysis and the Warburg effect by estrogen-related receptors [J]. Oncogene, 2013, 32 (16): 2079-2086.
  • 9Fradet A, Sorel H, Bouazza L, et al. Dual function of ERRalpha in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin[J]. Cancer Res, 2011, 71(17): 5728-5738.
  • 10Pooya S, Blaise S, Moreno Garcia M, et al. Methyl donor deficiency impairs fatty acid oxidation through PGC-lalpha hypomethylation and decreased ER-alpha, ERR-alpha, and HNF-4alpha in the rat liver [J]. J Hepatol, 2012, 57(2): 344-351.

同被引文献3

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部